Tradename:
Atacand plus
Atacand plus
Structure:
Each tablet contains:
32 mg condesartan and 25 mg hydrochlorothiazide
Auxiliary components:
Carmelose calcium, hydroxyprocelulose, iron oxide red, iron oxide yellow, lactose monohydrate, magnesium stearate, starch, macrogol.
Properties:
Angiotensin II is the primary vasoactive hormone of the renin-angiotensin-aldosterone system; it plays a role in the pathophysiology of arterial hypertension (AH), heart failure, and other cardiovascular disorders. The main physiological effects of angiotensin II, such as vasoconstriction, stimulation of aldosterone secretion, regulation of salt and water homeostasis, and stimulation of cell growth, are mediated by the type 1 receptor
Hydrochlorothiazide blocks sodium reabsorption, mainly in the distal renal tubules, and promotes the excretion of sodium, chloride and water. Renal excretion of potassium and magnesium increases depending on the dose of the drug, while calcium is reabsorbed to a greater extent. Hydrochlorothiazide reduces plasma and extracellular fluid volume and decreases cardiac output and blood pressure. With prolonged therapy, reduced peripheral resistance contributes to a decrease in blood pressure.
Candesartan and hydrochlorothiazide have an additive antihypertensive effect.
Indications:
Essential hypertension in cases where candesartan monotherapy with cilexetil or hydrochlorothiazide is insufficient.
Method of administration and dosage:
Take once daily before or after meals.
The recommended starting and usual maintenance dose of candesartan cilexetil is 16 mg once daily.
If sufficient control of blood pressure (BP) is not achieved after 4 weeks of treatment, the dose of 16 mg once a day can be increased to 32 mg once a day.
The recommended starting and usual maintenance dose of hydrochlorothiazide is 12.5 mg once daily. If sufficient control of blood pressure is not achieved after 4 weeks of treatment, the dose of 12.5 mg once a day, the dose can be increased to 25 mg once a day.
Contraindications:
– hypersensitivity to candesartan cilexetil or other components of the drug;
– severe hepatic impairment and / or cholestasis;
– pregnancy, breastfeeding;
– the simultaneous use of candesartan with aliskiren in patients with diabetes mellitus and / or moderate / severe renal failure (GFR <60 ml / min / 1.73 m2);
– children and adolescents up to 6 years old.
Precautions:
Double blockade of the renin-angiotensin-aldosterone system.
Double blockade of the renin-angiotensin-aldosterone system is associated with an increased risk of hypotension, gyneerkalemia, and impaired renal function (including acute renal failure) compared with monotherapy. Double blockade of RAAS with the use of an ACE inhibitor, ARB II, or aliskiren cannot be recommended for any patient, especially for patients with diabetic nephropathy.
In some cases, when the combined use of an ACE inhibitor and ARB II is absolutely indicated, careful observation by a specialist and mandatory monitoring of renal function, water-electrolyte balance, and blood pressure is necessary. This applies to the appointment of candesartan or valsartan as adjunctive therapy to ACE inhibitors in patients with chronic heart failure.
Side effects:
From the nervous system: dizziness / vertigo, headache.
Infections and infestations: respiratory tract infections.
Vascular disorders: arterial hypotension.
Metabolic and nutritional disorders: hyperkalemia.
On the part of the kidneys and urinary tract: impaired renal function, including renal failure in patients with a predisposition.
On the part of the blood and lymphatic system: leukopenia, neutropenia and agranulocytosis.
Metabolic and nutritional disorders: hyperkalemia, hyponatremia.
From the nervous system: dizziness, headache.
From the respiratory system: cough.
Gastrointestinal disturbances: nausea.
Hepatobiliary disorders: elevated liver enzyme levels, abnormal liver function, or hepatitis.
Storage:
In a cool dry place at a temperature not exceeding 30 degrees
Packaging:
The cardboard box contains 14 tablets and paper instructions.